Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 96, Issue 3, 2005, Pages 749-752

  Sutton, Gregory ^a   Blessing, John ^b   Hanjani, Parviz ^c   Kramer, Paul ^d  

^a Gynecologic Oncology St Vincent Hospitals and Health Services   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ABINGTON MEMORIAL HOSPITAL   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; Leiomyosarcoma; Uterus

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HUMAN; INFECTION; LEIOMYOSARCOMA; LEUKOPENIA; LUNG TOXICITY; LYMPHEDEMA; METABOLIC DISORDER; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERUS SARCOMA;

EID: 13844296902     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.11.036     Document Type: Article

References (14)

1. C. Zaloudek, and MR. Hendrickson Mesenchymal tumors of the uterus R.J. Kurman Blaustein' pathology of the female genital tract Fifth ed. 2002 Springer-Verlag New York 561
2. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, and A. Santoro Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
3. J. Vaage, E. Barbera-Guillem, R. Abra, A. Huang, and P. Working Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1994 1478 1484
4. C. Levenback, S.C. Rubin, P.M. McCormack, W.J. Hoskins, E.N. Atkinson, and J.L. Lewis Jr. Resection of pulmonary metastases from uterine sarcomas Gynecol. Oncol. 45 1992 202 205
5. G.P. Sutton, F.B. Stehman, H. Michael, P.C. Young, and C.E. Ehrlich Estrogen and progesterone receptors in uterine sarcomas Obstet. Gynecol. 68 1986 709 714
6. G.A. Omura, F.J. Major, J.A. Blessing, T.V. Sedlacek, J.T. Thigpen, and W.T. Creasman A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas Cancer 52 1983 626 632
7. H.B. Muss, B. Bundy, P.J. DiSaia, H.D. Homesley, W.C. Fowler Jr., and W. Creasman Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group) Cancer 55 1985 1648 1653
8. J.T. Thigpen, J.A. Blessing, and G.D. Wilbanks Cisplatin as second-line therapy in the treatment of patients with advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the gynecologic oncology group Am. J. Clin. Oncol. 9 1986 18 20
9. J.T. Thigpen, J.A. Blessing, J. Beecham, H. Homesley, and E. Yordan Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a gynecologic oncology group study J. Clin. Oncol. 9 1991 1962 1966
10. G.P. Sutton, J.A. Blessing, R.J. Barrett, and R. McGehee Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a gynecologic oncology group study Am. J. Obstet. Gynecol. 166 1992 556 559
11. G.P. Sutton, J.A. Blessing, and J.H. Malfetano Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a gynecologic oncology group study Gynecol. Oncol. 62 1996 226 229
12. G.P. Sutton, J.A. Blessing, and H. Ball A phase II study of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study Gynecol. Oncol. 74 1999 346 349
13. K.Y. Look, A. Sandler, J.A. Blessing, JA. Lucci III, and P.G. Rose Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a gynecologic oncology group (GOG) study Gynecol. Oncol. 92 2004 644 647
14. M.L. Hensley, R. Maki, E. Ventkatraman, G. Geller, M. Lovegren, and C. Aghajanian Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J. Clin. Oncol. 2 2002 2824 2831